



Two
1654

AMENDMENT TRANSMITTAL LETTER

Docket No.
ASZD-P01-555

Application No.
10/502069

Filing Date
December 9, 2004

Examiner
S. R. Gudibande

Art Unit
1654

Applicant(s): Korsgren et al.

Invention: USE OF MELAGATRAN FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	31	- 38 =	0	x	
Independent Claims	3	- 12 =	0	x	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:					0.00

☒ Large Entity

☐ Small Entity

☒ No additional fee is required for this amendment.

☐ Please charge Deposit Account No. _____ in the amount of \$ _____.
A duplicate copy of this sheet is enclosed.

☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☒ The Director is hereby authorized to charge and credit Deposit Account No. 18-1945
as described below. A duplicate copy of this sheet is enclosed.

☒ Credit any overpayment.

☒ Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.

Dated: September 29, 2005

David P. Halstead
Attorney Reg. No.: 44,735

ROPES & GRAY LLP
One International Place
Boston, Massachusetts 02110-2624
(617) 951-7449

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 9/29/05

Signature:

(John Mullins)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Korsgren, O.

Serial No: 10/502,069

Filed: December 9, 2004

For: USE OF MELAGATRAN FOR THE
MANUFACTURE OF A
MEDICAMENT FOR THE
TREATMENT FO TYPE 1
DIABETES MELLITUS

Attorney Docket No.: ASZD-P01-555

Art Unit: 1654

Examiner: GUDIBANDE, S. R.

Confirmation No.: 3992

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below:

September 29, 2005

Date of Signature
and of Mail Deposit


Jodi Lee Mullins

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REPLY AND AMENDMENT UNDER 37 CFR 1.111

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed July 1, 2005, in connection with the above application. Please enter the following amendments: